Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.

ABSTRACT:

Objective

We examined the efficacy and safety of galcanezumab after treatment cessation in randomized double-blind, placebo-controlled, migraine prevention studies (EVOLVE-1; EVOLVE-2).

Background

Galcanezumab is indicated for migraine prevention in adults.

Methods

Adults with episodic migraine were enrolled into EVOLVE-1 and EVOLVE-2, which randomized 858 and 915 patients, respectively, to galcanezumab 120 mg (an initial 240-mg loading dose), galcanezumab 240 mg, or placebo, administered subcutaneously once monthly for 6 months. After treatment completion or discontinuation, patients entered a 4-month posttreatment period. Efficacy and safety from the posttreatment periods are reported.

Results

Overall, 740 patients (EVOLVE-1) and 830 (EVOLVE-2) patients enter

SUBMITTER: Stauffer VL 

PROVIDER: S-EPMC6593785 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature